サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1565596

核医学の世界市場：タイプ (診断・治療)・用途・エンドユーザー・地域別の予測 (～2032年)

Global Nuclear Medicine Market Research Report Information by Type (Diagnosis and Therapeutic ), by Application, by End User, and by Region - Forecast till 2032
出版日: | 発行: Market Research Future | ページ情報: 英文 200 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
核医学の世界市場：タイプ (診断・治療)・用途・エンドユーザー・地域別の予測 (～2032年)
出版日: 2024年08月10日
発行: Market Research Future
ページ情報: 英文 200 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の核医学の市場規模は、2023年の98億4,000万米ドル、2024年の106億3,000万米ドルから、2032年には279億6,000万米ドルの規模に成長すると予測されています。

核医学の技術的進歩とヘルスケア産業における放射性同位元素の用途の拡大が市場成長の主な要因です。また、新しい技術のR&Dのための官民出資の拡大や、甲状腺関連疾患、呼吸器疾患、骨疾患、神経疾患などの正確な診断のための放射線治療を改善するためR&Dの増加によっても同市場の成長は牽引されています。

地域別展望

北米地域は製品が入手しやすく、活発な市場参入企業が存在することから、2023年の市場シェアは42.42%で最大の規模を示しました。欧州市場は、心臓病、アルツハイマー病、神経疾患に罹患する患者の増加、診断・治療プロセスの改善に対する需要の高まりから、予測期間中に大幅な成長が見込まれています。また、強化された放射性医薬品の採用、新製品の導入、M&Aによっても同地域市場は拡大しています。アジア太平洋地域は、心臓病患者の増加、PETやSPECTなどの診断機器を利用した高度な画像診断技術の市場開拓により、急速な成長が見込まれています。また、臨床医がSPECT画像技術を実施するためにガンマカメラを使用して複数の2Dおよび3D画像にアクセスすることが容易になっており、これが同地域の核医学市場を促進しています。

当レポートでは、世界の核医学の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

  • 促進要因
    • がんやその他の慢性疾患の罹患率の上昇
    • 核医学における技術的進歩
  • 抑制要因
    • 放射性医薬品の半減期の短さ
    • 訓練を受けた医療従事者の不足
  • 機会
    • 神経科用途における放射性医薬品の使用

第5章 市場要因分析

  • ポーターのファイブフォース分析
  • COVID-19が世界の核医学市場に与える影響

第6章 世界の核医学市場：タイプ別

  • 概要
  • 診断
    • SPECT放射性医薬品
    • PET放射性医薬品
  • 治療
    • アルファ放射体
    • ベータ放射体
    • 近接放射線治療同位元素

第7章 世界の核医学市場：用途別

  • 概要
  • 神経科
  • 心臓病
  • 腫瘍
    • 前立腺がん
    • 乳がん
    • 肺がん・気管支がん
    • 甲状腺がん
    • 大腸がん
    • その他
  • その他

第8章 世界の核医学市場：エンドユーザー別

  • 概要
  • 病院および診断センター
  • 研究機関
  • その他

第9章 世界の核医学市場：地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 市場シェア分析
  • 競合ダッシュボード
  • 公開企業の株式概要
  • 比較分析：主要企業の財務動向
  • 主な展開・成長戦略

第11章 企業プロファイル

  • GE HEALTHCARE
  • CARDINAL HEALTH
  • CURIUM
  • NOVARTIS AG
  • LANTHEUS
  • JUBILANT RADIOPHARMA
  • SIEMENS HEALTHINEERS
  • BAYER AG
  • ECKERT & ZIEGLER
  • BRACCO

第12章 データの引用

図表

LIST OF TABLES

  • TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
  • TABLE 2 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 3 GLOBAL NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 4 GLOBAL NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 5 GLOBAL NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 6 GLOBAL NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 7 GLOBAL NUCLEAR MEDICINE MARKET, FOR MO99/TC99M, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 8 GLOBAL NUCLEAR MEDICINE MARKET, FOR I-123, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 9 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 10 GLOBAL NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 11 GLOBAL NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 12 GLOBAL NUCLEAR MEDICINE MARKET, FOR F18, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 13 GLOBAL NUCLEAR MEDICINE MARKET, FOR C11 CHOLINE, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 14 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 15 GLOBAL NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 16 GLOBAL NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 17 GLOBAL NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 18 GLOBAL NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 19 GLOBAL NUCLEAR MEDICINE MARKET, FOR ACTINIUM-225 (AC-225), BY REGION, 2021-2032 (USD MILLION)
  • TABLE 20 GLOBAL NUCLEAR MEDICINE MARKET, FOR RADIUM-223 (RA-223), BY REGION, 2021-2032 (USD MILLION)
  • TABLE 21 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 22 GLOBAL NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 23 GLOBAL NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 24 GLOBAL NUCLEAR MEDICINE MARKET, FOR YTTRIUM-90 (Y-90), BY REGION, 2021-2032 (USD MILLION)
  • TABLE 25 GLOBAL NUCLEAR MEDICINE MARKET, FOR LUTETIUM-177 (LU-177), BY REGION, 2021-2032 (USD MILLION)
  • TABLE 26 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 27 GLOBAL NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 28 GLOBAL NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 29 GLOBAL NUCLEAR MEDICINE MARKET, FOR IODINE-125 (I-125), BY REGION, 2021-2032 (USD MILLION)
  • TABLE 30 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 31 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 32 GLOBAL NUCLEAR MEDICINE MARKET, FOR NEUROLOGY, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 33 GLOBAL NUCLEAR MEDICINE MARKET, FOR CARDIOLOGY, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 34 GLOBAL NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 35 GLOBAL NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 36 GLOBAL NUCLEAR MEDICINE MARKET, FOR PROSTATE CANCER, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 37 GLOBAL NUCLEAR MEDICINE MARKET, FOR BREAST CANCER, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 38 GLOBAL NUCLEAR MEDICINE MARKET, FOR LUNG AND BRONCHUS CANCER, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 39 GLOBAL NUCLEAR MEDICINE MARKET, FOR THYROID CANCER, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 40 GLOBAL NUCLEAR MEDICINE MARKET, FOR COLORECTAL CANCER, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 41 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 42 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 43 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 44 GLOBAL NUCLEAR MEDICINE MARKET, FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 45 GLOBAL NUCLEAR MEDICINE MARKET, FOR RESEARCH INSTITUTES, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 46 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 47 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION, 2021-2032 (USD MILLION)
  • TABLE 48 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2032 (USD MILLION)
  • TABLE 49 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 50 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 51 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 52 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 53 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 54 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 55 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 56 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 57 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 58 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 59 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 60 US NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 61 US NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 62 US NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 63 US NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 64 US NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 65 US NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 66 US NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 67 US NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 68 US NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 69 US NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 70 US NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 71 CANADA NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 72 CANADA NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 73 CANADA NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 74 CANADA NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 75 CANADA NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 76 CANADA NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 77 CANADA NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 78 CANADA NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 79 CANADA NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 80 CANADA NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 81 CANADA NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 82 MEXICO NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 83 MEXICO NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 84 MEXICO NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 85 MEXICO NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 86 MEXICO NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 87 MEXICO NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 88 MEXICO NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 89 MEXICO NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 90 MEXICO NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 91 MEXICO NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 92 MEXICO NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 93 EUROPE NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2032 (USD MILLION)
  • TABLE 94 EUROPE NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 95 EUROPE NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 96 EUROPE NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 97 EUROPE NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 98 EUROPE NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 99 EUROPE NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 100 EUROPE NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 101 EUROPE NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 102 EUROPE NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 103 EUROPE NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 104 EUROPE NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 105 GERMANY NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 106 GERMANY NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 107 GERMANY NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 108 GERMANY NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 109 GERMANY NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 110 GERMANY NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 111 GERMANY NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 112 GERMANY NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 113 GERMANY NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 114 GERMANY NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 115 GERMANY NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 116 FRANCE NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 117 FRANCE NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 118 FRANCE NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 119 FRANCE NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 120 FRANCE NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 121 FRANCE NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 122 FRANCE NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 123 FRANCE NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 124 FRANCE NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 125 FRANCE NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 126 FRANCE NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 127 UK NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 128 UK NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 129 UK NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 130 UK NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 131 UK NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 132 UK NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 133 UK NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 134 UK NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 135 UK NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 136 UK NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 137 UK NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 138 ITALY NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 139 ITALY NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 140 ITALY NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 141 ITALY NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 142 ITALY NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 143 ITALY NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 144 ITALY NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 145 ITALY NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 146 ITALY NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 147 ITALY NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 148 ITALY NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 149 SPAIN NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 150 SPAIN NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 151 SPAIN NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 152 SPAIN NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 153 SPAIN NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 154 SPAIN NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 155 SPAIN NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 156 SPAIN NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 157 SPAIN NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 158 SPAIN NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 159 SPAIN NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 160 REST OF EUROPE NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 161 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 162 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 163 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 164 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 165 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 166 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 167 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 168 REST OF EUROPE NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2032 (USD MILLION)
  • TABLE 169 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021-2032 (USD MILLION)
  • TABLE 170 REST OF EUROPE NUCLEAR MEDICINE MARKET, BY END USER, 2021-2032 (USD MILLION)
  • TABLE 171 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 172 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 173 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 174 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 175 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 176 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 177 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 178 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 179 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 180 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 181 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 182 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 183 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 184 CHINA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 185 CHINA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 186 CHINA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 187 CHINA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 188 CHINA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 189 CHINA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 190 CHINA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 191 CHINA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 192 CHINA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 193 CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 194 INDIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 195 INDIA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 196 INDIA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 197 INDIA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 198 INDIA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 199 INDIA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 200 INDIA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 201 INDIA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 202 INDIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 203 INDIA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 204 INDIA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 205 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 206 JAPAN: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 207 JAPAN: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 208 JAPAN: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 209 JAPAN: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 210 JAPAN: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 211 JAPAN: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 212 JAPAN: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 213 JAPAN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 214 JAPAN: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 215 JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 216 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 217 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 218 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 219 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 220 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 221 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 222 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 223 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 224 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 225 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 226 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 227 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 228 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 229 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 230 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 231 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 232 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 233 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 234 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 235 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 236 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 237 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 238 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 239 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 240 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 241 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 242 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 243 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 244 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 245 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 246 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 247 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 248 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 249 REST OT THE WORLD: NUCLEAR MEDICINE MARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 250 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 251 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 252 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 253 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 254 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 255 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 256 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 257 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 258 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 259 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 260 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 261 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 262 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 263 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 264 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 265 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 266 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 267 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 268 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 269 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 270 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 271 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 272 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 273 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 274 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 275 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 276 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 277 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 278 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 279 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 280 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 281 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 282 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 283 PUBLIC PLAYERS STOCK SUMMARY
  • TABLE 284 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
  • TABLE 285 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • TABLE 286 PARTNERSHIP
  • TABLE 287 ACQUISITION
  • TABLE 288 AGREEMENT
  • TABLE 289 COLLABORATION
  • TABLE 290 EXPANSION
  • TABLE 291 GE HEALTHCARE: PRODUCTS OFFERED
  • TABLE 292 CARDINAL HEALTH: PRODUCTS OFFERED
  • TABLE 293 CARDINAL HEALTH: KEY DEVELOPMENTS
  • TABLE 294 CURIUM: PRODCUTS OFFERED
  • TABLE 295 CURIUM: KEY DEVELOPMENTS
  • TABLE 296 NOVARTIS AG: PRODUCT OFFERED
  • TABLE 297 LANTHEUS: PRODUCT OFFERED
  • TABLE 298 LANTHEUS: KEY DEVELOPMENTS
  • TABLE 299 JUBILANT RADIOPHARMA: PRODUCT OFFERED
  • TABLE 300 JUBILANT RADIOPHARMA: KEY DEVELOPMENTS
  • TABLE 301 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
  • TABLE 302 BAYER AG: PRODUCTS OFFERED
  • TABLE 303 BAYER AG: KEY DEVELOPMENTS
  • TABLE 304 ECKERT & ZIEGLER: PRODUCT OFFERED
  • TABLE 305 ECKERT & ZIEGLER: KEY DEVELOPMENTS
  • TABLE 306 BRACCO: PRODUCT OFFERE

LIST OF FIGURES

  • FIGURE 1 GLOBAL NUCLEAR MEDICINE MARKET: STRUCTURE
  • FIGURE 2 GLOBAL NUCLEAR MEDICINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
  • FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL NUCLEAR MEDICINE MARKET
  • FIGURE 6 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE, 2023 & 2032 (USD MILLION)
  • FIGURE 7 GLOBAL NUCLEAR MEDICINE MARKET SHARE (%), BY TYPE,
  • FIGURE 8 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023 & 2032 (USD MILLION)
  • FIGURE 9 GLOBAL NUCLEAR MEDICINE MARKET SHARE (%), BY APPLICATION,
  • FIGURE 10 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER, 2023 & 2032 (USD MILLION)
  • FIGURE 11 GLOBAL NUCLEAR MEDICINE MARKET SHARE (%), BY END USER,
  • FIGURE 12 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION, 2023 & 2032 (USD MILLION)
  • FIGURE 13 GLOBAL NUCLEAR MEDICINE MARKET SHARE, BY REGION, 2023 (% SHARE)
  • FIGURE 14 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 15 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 16 EUROPE NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 17 EUROPE NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 18 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 19 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET SHARE (%), BY COUNTRY,
  • FIGURE 20 REST OT THE WORLD: NUCLEAR MEDICINE MARKET, BY REGION, 2023 & 2032 (USD MILLION)
  • FIGURE 21 REST OT THE WORLD: NUCLEAR MEDICINE MARKET SHARE (%), BY REGION,
  • FIGURE 22 NUCLEAR MEDICINE MARKET PLAYERS: COMPETITIVE ANALSIS,
  • FIGURE 23 COMPETITOR DASHBOARD: GLOBAL NUCLEAR MEDICINE MARKET
  • FIGURE 24 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 25 GE HEALTHCARE: SWOT ANALYSIS
  • FIGURE 26 CARDINAL HEALTH: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 27 CARDINAL HEALTH: SWOT ANALYSIS
  • FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 NOVARTIS AG.: SWOT ANALYSIS
  • FIGURE 30 LANTHEUS: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 SIEMENS HEALTHINEERS: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 32 SIEMENS HEALTHINEERS: SWOT ANALYSIS
  • FIGURE 33 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 34 BAYER AG: SWOT ANALYSIS
  • FIGURE 35 ECKERT & ZIEGLER: FINANCIAL OVERVIEW SNAPSHOT
目次
Product Code: MRFR/Pharma/5211-CR

Global Nuclear Medicine Market Research Report Information by Type (Diagnosis [SPECT Radiopharmaceuticals {Tc99m, I-123, and Others} and PET Radiopharmaceuticals {F18, C11 Choline, and Others}] and Therapeutic (Alpha Emitters [Actinium-225 (Ac-225), Radium-223 (Ra-223), and Others], Beta Emitters [Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Others], and Brachytherapy Isotopes [Iodine-125 (I-125) and Others]), by Application (Neurology, Cardiology, Oncology [Prostate Cancer, Breast Cancer, Lung and Bronchus Cancer, Thyroid Cancer, Colorectal Cancer, and Others], and Others), by End User (Hospitals & Diagnostic Centers, Research Institutes, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview

In 2023, the nuclear medicine market was estimated to be worth USD 9.84 billion. The Nuclear Medicine Market industry is anticipated to expand from USD 10.63 billion in 2024 to USD 27.96 billion by 2032. Technological advancements in nuclear medicine and the increasing applications of radioisotopes in the healthcare industry are the primary factors driving market growth. Additionally, the nuclear medicine market is being driven by the expansion of public-private funding for the research and development of new techniques, as well as the increasing research and development in the pharmaceutical and biotechnology industries to improve radiotherapy for the accurate diagnosis of diseases such as thyroid-related diseases, respiratory diseases, bone diseases, neurological diseases, and others.

Market segment insights

The Nuclear Medicine Market has been divided into two categories: diagnostic and therapeutic. The Nuclear Medicine Market has been segmented into neurology, cardiology, oncology, and other fields based on application. The Nuclear Medicine Market has been categorized as hospitals & diagnostic centers, research institutes, and others based on the end user.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. As a result of the availability of products and the presence of active industry participants in the region, North America accounted for the largest market share of 42.42% in 2023. The European market is expected to experience substantial growth during the forecast period because of the growing number of individuals suffering from heart disease, Alzheimer's disease, and neurological problems, as well as the increasing demand for improved diagnostic and treatment processes. Additionally, the nuclear medicine market is expanding because of the adoption of enhanced radiopharmaceuticals, new product introductions, and mergers and acquisitions. The market in Asia-Pacific is expected to experience rapid growth because of the increasing number of cardiac patients and the development of advanced imaging techniques that utilize diagnostic instruments such as PET and SPECT. Additionally, clinicians are being facilitated in their access to multiple 2D and 3D images using a gamma camera to perform SPECT imaging techniques, which is propelling the nuclear medicine market in the region. Moreover, the nuclear medicine market in Japan accounted for the largest market share in 2023, while the nuclear medicine market in India is the fastest-growing market in the Asia-Pacific region.

Major Players

Novartis AG (Switzerland), GE Healthcare (US), Cardinal Health (US), Eckert & Ziegler Group (Germany), Lantheus (US), Jubilant Radiopharma (Canada), Bayer AG (Germany), Siemens Healthineers (Germany), Curium Pharma (France), Bracco (Italy), and others are among the key companies in the Nuclear Medicine Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
    • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
    • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
  • 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
  • 3.7 DATA FORECASTING
    • 3.7.1 DATA FORECASTING TYPE
  • 3.8 DATA MODELING
    • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.8.2 DATA MODELING:
  • 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
    • 4.2.2 TECHNOLOGICAL ADVANCEMENTS IN NUCLEAR MEDICINE
  • 4.3 RESTRAINTS
    • 4.3.1 SHORT HALF-LIFE OF RADIOPHARMACEUTICALS
    • 4.3.2 SHORTAGE OF TRAINED MEDICAL PERSONNEL
  • 4.4 OPPORTUNITY
    • 4.4.1 USE OF RADIOPHARMACEUTICALS IN NEUROLOGICAL APPLICATIONS

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES MODEL
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 THREAT OF SUBSTITUTES
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 IMPACT OF COVID-19 ON THE GLOBAL NUCLEAR MEDICINE MARKET

6 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE

  • 6.1 OVERVIEW
  • 6.2 DIAGNOSTIC
    • 6.2.1 SPECT RADIOPHARMACEUTICALS
      • 6.2.1.1 MO99/TC99M
      • 6.2.1.2 I-123
      • 6.2.1.3 OTHERS
    • 6.2.2 PET RADIOPHARMACEUTICALS
      • 6.2.2.1 F18
      • 6.2.2.2 C11 CHOLINE
      • 6.2.2.3 OTHERS
  • 6.3 THERAPEUTIC
    • 6.3.1 ALPHA EMITTERS
      • 6.3.1.1 ACTINIUM-225 (AC-225)
      • 6.3.1.2 RADIUM-223 (RA-223)
      • 6.3.1.3 OTHERS
    • 6.3.2 BETA EMITTERS
      • 6.3.2.1 YTTRIUM-90 (Y-90)
      • 6.3.2.2 LUTETIUM-177 (LU-177)
      • 6.3.2.3 OTHERS
    • 6.3.3 BRACHYTHERAPY ISOTOPE
      • 6.3.3.1 IODINE-125 (I-125)
      • 6.3.3.2 OTHERS

7 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION

  • 7.1 OVERVIEW
  • 7.2 NEUROLOGY
  • 7.3 CARDIOLOGY
  • 7.4 ONCOLOGY
    • 7.4.1 PROSTATE CANCER
    • 7.4.2 BREAST CANCER
    • 7.4.3 LUNG AND BRONCHUS CANCER
    • 7.4.4 THYROID CANCER
    • 7.4.5 COLORECTAL CANCER
    • 7.4.6 OTHERS
  • 7.5 OTHERS

8 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 HOSPITALS AND DIAGNOSTIC CENTERS
  • 8.3 RESEARCH INSTITUTES
  • 8.4 OTHERS

9 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
    • 9.2.3 MEXICO
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 FRANCE
    • 9.3.3 UK
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 INDIA
    • 9.4.3 JAPAN
    • 9.4.4 SOUTH KOREA
    • 9.4.5 AUSTRALIA
    • 9.4.6 REST OF ASIA-PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST & AFRICA
    • 9.5.2 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET SHARE ANALYSIS,
  • 10.3 COMPETITOR DASHBOARD
  • 10.4 PUBLIC PLAYERS STOCK SUMMARY
  • 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
  • 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
    • 10.6.2 PARTNERSHIP
    • 10.6.3 ACQUISITION
    • 10.6.4 AGREEMENT
    • 10.6.5 COLLABORATION
    • 10.6.6 EXPANSION

11 COMPANY PROFILES

  • 11.1 GE HEALTHCARE
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS/SERVICES OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 CARDINAL HEALTH
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 CURIUM
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 KEY STRATEGIES
  • 11.4 NOVARTIS AG
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGIES
  • 11.5 LANTHEUS
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 KEY STRATEGIES
  • 11.6 JUBILANT RADIOPHARMA
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 KEY STRATEGIES
  • 11.7 SIEMENS HEALTHINEERS
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 SWOT ANALYSIS
    • 11.7.6 KEY STRATEGIES
  • 11.8 BAYER AG
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 SWOT ANALYSIS
    • 11.8.6 KEY STRATEGY
  • 11.9 ECKERT & ZIEGLER
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 KEY STRATEGIES
  • 11.10 BRACCO
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 KEY STRATEGY

12 DATA CITATIONS